- Home
- FOF vs GLSI Comparison
FOF vs GLSI Comparison
Compare FOF & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOF | GLSI |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 372.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FOF | GLSI |
|---|---|---|
| Price | $14.08 | $23.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 80.5K | ★ 131.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.07% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.97 | $7.78 |
| 52 Week High | $15.04 | $34.10 |
Technical Indicators
Market Signals| Indicator | FOF | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 44.38 |
| Support Level | $12.87 | $20.82 |
| Resistance Level | $14.50 | $31.87 |
| Average True Range (ATR) | 0.19 | 2.15 |
| MACD | -0.07 | -0.44 |
| Stochastic Oscillator | 13.48 | 28.33 |
Price Performance
Historical ComparisonAbout FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.